JGC
TARS icon

J. Goldman & Co’s Tarsus Pharmaceuticals TARS Stock Holding History

J. Goldman & Co’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-7,100
Closed -$393K – 629
2024
Q4 		$393K Sell
7,100
-87,400
-92% -$3.97M 0.01% 379
2024
Q3 		$3.11M Buy
+94,500
New +$2.66M 0.09% 205

Other funds holding TARS

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

J. Goldman & Co's TARS Position: Q1 2026 in Review

J. Goldman & Co increased its Tarsus Pharmaceuticals (TARS) stake by 439% in Q1 2026, buying an estimated $827K and bringing the position to 14,541 shares worth $1.02M. The position accounts for 0.03% of the portfolio, ranked #415.

J. Goldman & Co first reported a position in TARS in Q2 2021 and has held it in 19 quarters since. The position peaked at $18.3M in Q3 2024. 253 funds tracked by Wall St. Rank hold TARS as of Q1 2026.

  • J. Goldman & Co held 14,541 shares of Tarsus Pharmaceuticals worth $1.02M as of Q1 2026.
  • J. Goldman & Co bought 11,842 Tarsus Pharmaceuticals shares in Q1 2026, an estimated $827K.
  • Tarsus Pharmaceuticals made up 0.03% of J. Goldman & Co's portfolio in Q1 2026, its #415 holding.
  • J. Goldman & Co first reported a position in Tarsus Pharmaceuticals in Q2 2021 and has held it in 19 quarters since.
  • J. Goldman & Co's Tarsus Pharmaceuticals position peaked at $18.3M in Q3 2024.
  • 253 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.